Skip to main content

Alimera Sciences, Inc. (ALIM)

NASDAQ: ALIM · IEX Real-Time Price · USD
5.28 -0.51 (-8.81%)
Nov 26, 2021 1:00 PM EST - Market closed
Market Cap36.63M
Revenue (ttm)58.84M
Net Income (ttm)-1.24M
Shares Out6.94M
EPS (ttm)-0.20
PE Ration/a
Forward PE65.79
Dividendn/a
Ex-Dividend Daten/a
Volume13,285
Open5.74
Previous Close5.79
Day's Range5.25 - 5.80
52-Week Range3.94 - 12.25
Beta1.67
AnalystsStrong Buy
Price Target14.83 (+180.9%)
Earnings DateOct 28, 2021

About ALIM

Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician o...

IndustryPharmaceuticals
IPO DateApr 22, 2010
CEOC. Daniel Myers
Employees130
Stock ExchangeNASDAQ
Ticker SymbolALIM
Full Company Profile

Financial Performance

In 2020, ALIM's revenue was $50.82 million, a decrease of -5.79% compared to the previous year's $53.94 million. Losses were -$5.34 million, -48.87% less than in 2019.

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for ALIM stock is "Strong Buy." The 12-month stock price forecast is 14.83, which is an increase of 180.87% from the latest price.

Price Target
$14.83
(180.87% upside)
Analyst Consensus: Strong Buy

News

Alimera Sciences to Participate in Upcoming November 2021 Investor Conferences

ATLANTA, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners conce...

2 weeks ago - GlobeNewsWire

Alimera Sciences (ALIM) Reports Q3 Loss, Misses Revenue Estimates

Alimera Sciences (ALIM) delivered earnings and revenue surprises of -15.38% and -1.20%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

4 weeks ago - Zacks Investment Research

Alimera Sciences Announces Third Quarter 2021 Financial Results

ATLANTA, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concern...

4 weeks ago - GlobeNewsWire

Alimera Sciences to Report Third Quarter 2021 Financial Results on Thursday, October 28, 2021, and Provide Corporate ...

Conference Call to be held Thursday, October 28, 2021, at 9:00am Eastern Time Conference Call to be held Thursday, October 28, 2021, at 9:00am Eastern Time

1 month ago - GlobeNewsWire

Analysts Estimate Alimera Sciences (ALIM) to Report a Decline in Earnings: What to Look Out for

Alimera Sciences (ALIM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Recent 24-Month Real-World PALADIN Data Demonstrate the Ability of ILUVIEN® to Significantly Reduce Treatment Burden ...

PALADIN Study Data Presented at the American Society of Retina Specialists Shows That Post-ILUVIEN, the Percentage of Eyes Receiving One Yearly Treatment or Less Increased 3.2-Fold Compared to Pre-ILUVIEN

1 month ago - GlobeNewsWire

Alimera Sciences, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference

ATLANTA, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be i...

2 months ago - GlobeNewsWire

Alimera Sciences Announces National Pricing and Reimbursement Granted for ILUVIEN® for DME in Belgium

ATLANTA, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic ...

3 months ago - GlobeNewsWire

New Strong Sell Stocks for August 19th

ALIM, BEEM, CDR, ENTX, and IDEX have been added to the Zacks Rank #5 (Strong Sell) List on August 19, 2021.

Other symbols:BEEMCDRENTXIDEX
3 months ago - Zacks Investment Research

Alimera Sciences (ALIM) Q2 Earnings and Revenues Miss Estimates

Alimera Sciences (ALIM) delivered earnings and revenue surprises of -39.20% and -6.85%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Recap: Alimera Sciences Q2 Earnings

Shares of Alimera Sciences (NASDAQ:ALIM) moved higher by 5.3% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 252.94% year over year to $0.78, w...

3 months ago - Benzinga

Alimera Sciences Announces Second Quarter 2021 Financial Results

ATLANTA, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription opht...

3 months ago - GlobeNewsWire

Alimera Sciences to Report Second Quarter 2021 Financial Results on Friday, August 13, 2021, and Provide Corporate Up...

Conference Call to be held Friday, August 13, 2021, at 9:00 am Eastern Time Conference Call to be held Friday, August 13, 2021, at 9:00 am Eastern Time

3 months ago - GlobeNewsWire

Alimera Sciences (ALIM) Earnings Expected to Grow: Should You Buy?

Alimera Sciences (ALIM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

Alimera Sciences, Inc. to Present at the Summer Solstice – Best Ideas from the Buy Side Conference on June 2, 2021

ATLANTA, May 27, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic...

6 months ago - GlobeNewsWire

Alimera Sciences Appoints David Dyer, M.D. as Chief Retina Specialist

ATLANTA, May 17, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, has announced the...

6 months ago - GlobeNewsWire

Alimera Sciences (ALIM) Reports Q1 Loss, Lags Revenue Estimates

Alimera Sciences (ALIM) delivered earnings and revenue surprises of -26.00% and -3.33%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Alimera Sciences Announces First Quarter 2021 Financial Results

ATLANTA, April 28, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription oph...

6 months ago - GlobeNewsWire

Earnings Outlook For Alimera Sciences

On Wednesday, April 28, Alimera Sciences (NASDAQ:ALIM) will report its last quarter's earnings. Here is Benzinga's preview of the company's release.

7 months ago - Benzinga

Alimera Science's Innovative Treatment for Diabetic Macular Edema Vision Loss Lasts for up to 3 Years

Intravitreal Implant Provides a Daily Microdose Release to Reduce Disease Recurrence   Amid required stay-at-home orders, many have paused or canceled doctor's appointments over the past 12 months. Rece...

7 months ago - Benzinga

Alimera Sciences Receives $20 Million From Ocumension Therapeutics

ATLANTA, April 14, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription ophthalmic...

7 months ago - GlobeNewsWire

Alimera Sciences to Present at the Zooming with LD Micro Virtual Conference on April 15, 2021

ATLANTA, April 09, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalm...

7 months ago - GlobeNewsWire

Alimera Sciences to Present at the H.C. Wainwright Global Life Sciences Conference

ATLANTA, March 02, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalm...

8 months ago - GlobeNewsWire

Alimera Sciences Reports Fourth Quarter and 2020 Results

Fourth Quarter Highlights:

9 months ago - GlobeNewsWire

Alimera Sciences Continues Global Geographic Expansion With Launch of ILUVIEN in Finland for Both Indications

ATLANTA, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription ophthalmic ...

9 months ago - GlobeNewsWire